Roche says Ale­cen­sa helps keep ALK-pos­i­tive lung can­cer at bay af­ter surgery as it looks to ex­pand la­bel

Roche’s alec­tinib, mar­ket­ed as Ale­cen­sa, helped cer­tain lung can­cer pa­tients stay dis­ease-free for longer fol­low­ing surgery in a Phase III study, the big phar­ma an­nounced Fri­day.

Roche’s sub­sidiary Genen­tech test­ed the drug in a Phase III open-la­bel study with 257 pa­tients with ALK-pos­i­tive non-small cell lung can­cer (NSCLC) who had their stage IB to II­IA tu­mors re­moved. Com­pared to those in the con­trol arm who re­ceived chemother­a­py fol­low­ing surgery, those who re­ceived alec­tinib had a re­duced risk of their can­cer re­turn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER